🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Transarterial Chemoembolization

Regional Lymph Node Metastasis and Survival Outcomes in Advanced HCC NCT06876753n/a2 sites📍 Nanjing📍 Nanjing Zhongda Hospital Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC NCT05608200Phase 31 site📍 Guangzhou Second Affiliated Hospital of Guangzhou Medical University · Tests: Lenvatinib, sintilimab plus TACE, Lenvatinib plus TACE The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma NCT04803994Phase 372 sites📍 Graz📍 Innsbruck📍 Klagenfurt Institut für Klinische Krebsforschung IKF GmbH at Krankenha… · Tests: Atezolizumab, Bevacizumab, TACE Prospective Collection of Therapeutic Efficacy and Safety Data in Patients with Unresectable Hepatocellular Carcinoma NCT06788353n/a1 site📍 Guangzhou Sun Yat-sen University HAIC vs. TACE Combined With Sintilimab and Bevacizumab for Intermediate HCC (Beyond Up-To-Seven) NCT07594340Phase 31 site📍 Guangzhou Binkui Li · Tests: Procedure (FOLFOX-HAIC): Max 4 cycles within first 16 weeks., TACE (transarterial chemoembolization) combined with targ… Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular Carcinamo NCT07239245Phase 24 sites📍 Beijing📍 Zhengzhou📍 Shenyang Cancer Institute and Hospital, Chinese Academy of Medical S… · Tests: Atezolizumab, Bevacizumab, Transarterial chemoembolization (TACE) A Phase II/III Trial Comparing Transarterial Tirapazamine Embolization (TATE) With cTACE for Intermediate-stage Liver Cancer. NCT06844357Phase 2, Phase 32 sites📍 Nanjing📍 Lishui Zhejiang Raygene Pharmaceuticals Co., Ltd · Tests: tirapazamine, Transarterial Embolization (TAE), TACE A Multicenter Prospective Study on the Performance of Spectral CT for Evaluating Treatment Response After TACE in Hepatocellular Carcinoma NCT07351669n/a1 site📍 Nanjing Zhongda Hospital Transarterial Chemoembolization (TACE) Versus TACE Plus Stereotactic Body Radiation Therapy (SBRT) in Liver Carcinoma NCT03895359Phase 31 site📍 London London Health Sciences Centre Research Institute OR Lawson … · Tests: Stereotactic Body Radiation, Transarterial Chemoembolization Registry of Minimally Invasive Cancer Treatment Using Spectral Angio-CT Image Guidance NCT07636148n/a3 sites📍 Lyon📍 Créteil📍 Leiden Mark C Burgmans, MD PhD qDSA Blood Flow Measurement in Patients Undergoing TAE of the Liver NCT06971991NA1 site📍 Madison University of Wisconsin, Madison · Tests: qDSA Blood Flow Measurement Comparison of SBRT and SIRT With Combination IO for Locally-advanced, Unresectable HCCs (BIIRTH) NCT07293468Phase 2, Phase 31 site📍 Hong Kong Tuen Mun Hospital · Tests: Transarterial chemoembolization (TACE), Stereotactic Body Radiation Therapy (SBRT), SIRT Yttrium-90, Atezolizumab &… A Study of Standard Of Care Versus Radio Ablation in Early Stage HCC NCT07628751NA2 sites📍 Waratah📍 Toronto University Health Network, Toronto · Tests: Stereotactic Ablative Body Radiotherapy (SABR), Therapies Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma NCT04472767Phase 21 site📍 Orange University of California, Irvine · Tests: Nivolumab, Ipilimumab, Cabozantinib, Transarterial Chemoembolization DEB-TACE vs cTACE in HCC After TIPS NCT07322848Phase 31 site📍 Guangzhou First Affiliated Hospital, Sun Yat-Sen University · Tests: DEB-TACE, cTACE TACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma NCT06485466Phase 31 site📍 Chengdu Guohui Xu · Tests: TACE plus camrelizumab and apatinib, Camrelizumab and apatinib DEB-TACE Prior to Liver Transplantation in the Treatment of HCC NCT06353126Phase 41 site📍 Shanghai RenJi Hospital · Tests: DEB-TACE To Evaluate Safety and Efficacy of FB-1603 in Hepatocellular Carcinoma Patient Receiving Transarterial Chemoembolization NCT06478719Phase 1, Phase 22 sites📍 Taipei📍 Taoyuan Febico Biomedical Corp. · Tests: Placebo, FB-1603 A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma NCT06371157Phase 34 sites📍 Zhengzhou📍 Changsha📍 Nanjing Akeso · Tests: AK104, Lenvatinib, TACE, Placebo for AK104, Placebo for Lenvatinib Transarterial Chemoembolization (TACE) Plus ABCB1 Inhibition Versus TACE Alone in Patients With Hepatocellular Carcinoma NCT07302919Phase 2, Phase 33 sites📍 Basel📍 Geneva📍 Sankt Gallen University Hospital, Basel, Switzerland · Tests: DEB-DoxNic-TACE, current standard of care Comparison of Response Between Combination of Transarterial Chemoembolization and Lenvatinib Therapy Versus Lenvatinib Monotherapy in Patients With Unresectable Hepatocellular Carcinoma NCT07408804NA1 site📍 Dhaka Bangladesh Medical University · Tests: TACE (transarterial chemoembolization) combined with targeted therapy (Lenvatinib), Lenvatinib Drug-Eluting Bead-Based Transarterial Chemoembolization (DEB-TACE) as a Local Salvage Therapy for Large Lesions in Relapsed and Refractory Diffuse Large B-Cell Lymphoma NCT07198230n/a1 site📍 Fuzhou Ting YANG Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma NCT05842174Phase 1, Phase 21 site📍 Philadelphia VA Office of Research and Development · Tests: Hydroxychloroquine, Lipiodol, Placebo A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Participants With Incurable/Non-metastatic HCC NCT07521852Phase 22 sites📍 Fuzhou📍 Shanghai TaiRx, Inc. · Tests: CVM-1118 + Sintilimab + TACE Adjuvant TACE in HCC With High-risk Recurrence Factors NCT07417397Phase 31 site📍 Nanning Guangxi Medical University · Tests: Adjuvant transarterial chemoembolization, Intensive follow-up Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC NCT07186621Phase 31 site📍 Beijing Cancer Institute and Hospital, Chinese Academy of Medical S… · Tests: Sintilimab, radiotherapy, TACE Lenvatinib Plus DEB-TACE and HAIC vs. Lenvatinib Plus DEB-TACE for Large HCC With PVTT NCT06492395Phase 31 site📍 Guangzhou Second Affiliated Hospital of Guangzhou Medical University · Tests: Len+DEB-TACE+HAIC, Len+DEB-TACE DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC NCT06397235Phase 21 site📍 Guangzhou Second Affiliated Hospital of Guangzhou Medical University · Tests: DEB-TACE+HAIC, DEB-TACE Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular Carcinoma NCT06911255Phase 1, Phase 21 site📍 Seoul Yoon Jun Kim · Tests: Tremelimumab Plus Durvalumab (MEDI4736), Transarterial chemoembolization (TACE) Lenvatinib, Sintilimab, and DEB-TACE With/Without HAIC for HCC >7 cm With PVTT NCT06904183Phase 21 site📍 Guangzhou Second Affiliated Hospital of Guangzhou Medical University · Tests: LEN+SIN+DEB-TACE+HAIC, LEN+SIN+DEB-TACE
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy